{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:00:14Z","timestamp":1773867614882,"version":"3.50.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["TL1DK132770"],"award-info":[{"award-number":["TL1DK132770"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","award":["R00HL172303"],"award-info":[{"award-number":["R00HL172303"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005881","name":"Hemostasis and Thrombosis Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005881","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rpth.2025.103224","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:09:38Z","timestamp":1760551778000},"page":"103224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Patient-Reported Outcomes Measurement Information System perspective of adults with long-standing atypical hemolytic uremic syndrome"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7382-2222","authenticated-orcid":false,"given":"Anne","family":"Hubben","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Len","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2025.103224_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1182\/asheducation-2016.1.217","article-title":"Atypical hemolytic uremic syndrome","volume":"2016","author":"Afshar-Kharghan","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2025.103224_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MOP.0b013e32835df48a","article-title":"Complement disorders and hemolytic uremic syndrome","volume":"25","author":"Joseph","year":"2013","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.rpth.2025.103224_bib3","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103224_bib4","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rpth.2025.103224_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","article-title":"Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial","volume":"68","author":"Fakhouri","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2025.103224_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100855","article-title":"Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials","volume":"6","author":"Dixon","year":"2024","journal-title":"Kidney Med"},{"key":"10.1016\/j.rpth.2025.103224_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1182\/blood.2022018833","article-title":"Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study","volume":"142","author":"Brocklebank","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103224_bib9","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.kint.2024.09.012","article-title":"Forum Participants. Outcomes from the International Society of Nephrology Hemolytic Uremic Syndromes International Forum","volume":"106","author":"Kavanagh","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.rpth.2025.103224_bib10","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.ekir.2019.07.016","article-title":"Eculizumab safety: five-year experience from the Global Atypical Hemolytic Uremic Syndrome Registry","volume":"4","author":"Rondeau","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.rpth.2025.103224_bib11","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.rpth.2025.103224_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.914338","article-title":"Valuing the \"burden\" and impact of rare diseases: a scoping review","volume":"13","author":"Delaye","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.rpth.2025.103224_bib13","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-022-02343-4","article-title":"Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases","volume":"17","author":"Bogart","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"Suppl 3","key":"10.1016\/j.rpth.2025.103224_bib14","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s11606-014-2892-z","article-title":"Patient-reported outcomes in clinical trials of rare diseases","volume":"29","author":"Basch","year":"2014","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.rpth.2025.103224_bib15","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1007\/s11136-018-1842-3","article-title":"PROMIS\u00ae-29 v2.0 profile physical and mental health summary scores","volume":"27","author":"Hays","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1016\/j.rpth.2025.103224_bib16","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12882-024-03770-0","article-title":"Treatment discontinuation in adults with atypical hemolytic uremic syndrome (aHUS): a qualitative study of international experts\u2019 perspectives with associated cost-consequence analysis","volume":"25","author":"Germeni","year":"2024","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib17","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.ekir.2024.04.047","article-title":"Living with atypical hemolytic uremic syndrome in the Netherlands: patient and family perspective","volume":"9","author":"Bouwmeester","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.rpth.2025.103224_bib18","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1053\/j.ajkd.2023.09.007","article-title":"Patient-reported outcome measures for patients with CKD: the case for Patient-Reported Outcomes Measurement Information System (PROMIS) tools","volume":"83","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2025.103224_bib19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1053\/j.ajkd.2022.12.018","article-title":"Assessing fatigue in patients receiving kidney replacement therapy using PROMIS computer adaptive testing","volume":"82","author":"Dano","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.rpth.2025.103224_bib20","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1007\/s00467-014-2858-8","article-title":"Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a Midwest Pediatric Nephrology Consortium study","volume":"29","author":"Selewski","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s11136-018-2058-2","article-title":"Validation of the Patient-Reported Outcomes Measurement Information System (PROMIS)-57 and -29 item short forms among kidney transplant recipients","volume":"28","author":"Tang","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.rpth.2025.103224_bib22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1159\/000508919","article-title":"The relationship between dialysis metrics and patient-reported cognition, fatigue, and physical function","volume":"6","author":"Sturgill","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.rpth.2025.103224_bib23","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12888-023-05249-y","article-title":"Depression among patients with chronic kidney disease, associated factors, and predictors: a cross-sectional study","volume":"23","author":"Bahall","year":"2023","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.rpth.2025.103224_bib24","first-page":"40","article-title":"Fatigue as a residual symptom of depression","volume":"8","author":"Targum","year":"2011","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.rpth.2025.103224_bib25","first-page":"9","article-title":"Symptoms of fatigue and sleepiness in major depressive disorder","volume":"67","author":"Baldwin","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.rpth.2025.103224_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2024.1409250","article-title":"Subjective brain fog: a four-dimensional characterization in 25,796 participants","volume":"18","author":"Alim-Marvasti","year":"2024","journal-title":"Front Hum Neurosci"},{"key":"10.1016\/j.rpth.2025.103224_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-019-1314-1","article-title":"Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study","volume":"20","author":"Menne","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib28","first-page":"325","article-title":"Silent cerebral infarction during immune TTP remission: prevalence, predictors, and impact on cognition","volume":"142","author":"Chaturvedi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103224_bib29","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.ekir.2020.05.003","article-title":"Functional assessment of fatigue and other patient-reported outcomes in patients enrolled in the Global aHUS Registry","volume":"5","author":"Greenbaum","year":"2020","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.rpth.2025.103224_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/0886022X.2018.1427110","article-title":"Evaluation of health-related quality of life in hemolytic uraemic syndrome patients treated with eculizumab: a systematic evaluation on basis of EMPRO","volume":"40","author":"Mukherjee","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.rpth.2025.103224_bib31","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00467-016-3569-0","article-title":"Long-term health-related quality of life and psychological adjustment in children after haemolytic-uraemic syndrome","volume":"32","author":"Werner","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","article-title":"Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome","volume":"5","author":"Chaturvedi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103224_bib33","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2025.103224_bib34","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/bloodadvances.2021006416","article-title":"Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation","volume":"7","author":"Acosta-Medina","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2025.103224_bib35","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.2215\/CJN.01880221","article-title":"Evaluation of PROMIS Preference Scoring System (PROPr) in patients undergoing hemodialysis or kidney transplant","volume":"16","author":"Zhang","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.rpth.2025.103224_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102474","volume":"8","author":"van Hoorn","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2025.103224_bib37","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1111\/jth.15454","article-title":"Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands","volume":"19","author":"van Balen","year":"2021","journal-title":"J Thromb Haemost"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005485?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037925005485?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T13:50:34Z","timestamp":1773841834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037925005485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2475037925005485"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103224","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Patient-Reported Outcomes Measurement Information System perspective of adults with long-standing atypical hemolytic uremic syndrome","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2025.103224","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"103224"}}